Overexpression of c-Abl predicts unfavorable outcome in epithelial ovarian cancer

Gynecologic Oncology

Volumn 131, Issue 1, 2013, Pages 69-76

  Zhou, Suiyang ^a   Tang, Liangdan ^a   Wang, Haixia ^a   Dai, Jiemin ^a   Zhang, Jing ^a   Shen, Liyuan ^a   Ng, Shu Wing ^b   Berkowitz, Ross S ^b  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

C Abl; Epithelial ovarian cancer; Invasion; Metastasis; Prognosis

Indexed keywords

ABELSON KINASE; CA 125 ANTIGEN;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; OVARY; OVARY CANCER; OVARY TUMOR; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SURVIVAL PREDICTION; TUMOR INVASION; WESTERN BLOTTING;

EID: 84885325980     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.06.031     Document Type: Article

References (33)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60(5): 277-300.
2. Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, Schilder RJ, et al. Focus on epithelial ovarian cancer. Cancer Cell 2004;5(1): 19-24.
3. Tang L, Yang J,Ng SK, RodriguezN, ChoiPW, Vitonis A, et al. Autoantibody profiling to identify biomarkers of key pathogenic pathways in mucinous ovarian cancer. Eur J Cancer 2010;46(1): 170-9.
4. Gentry-Maharaj A, Menon U. Screening for ovarian cancer in the general population. Best Pract Res Clin Obstet Gynaecol 2012;26(2): 243-56.
5. Tan David SP, Agarwal R, Kaye SB. Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol 2006;7(11): 925-34.
6. Lau MT, Leung Peter CK. The PI3K/Akt/mTOR signaling pathway mediates insulin-like growth factor 1 induced E-cadherin down-regulation and cell proliferation in ovarian cancer cell. Cancer Lett 2012;326(2): 191-8.
7. Guerra F, Perrone AM, Kurelac I, Santini D, Ceccarelli C, Cricca M, et al. J Clin Oncol 2012;30(36): 373-8.
8. Molina R, Escudero JM, Auge JM. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumour Biol 2011;32(6): 1087-95.
9. Li H, Cai KQ, Godwin AK, Zhang RG. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells. Mol Cancer Res 2010;8(12): 1610-8.
10. Bolitho C, Hahn MA, Baxter RC, Marsh DJ. The chemokine CXCL 1 induces proliferation in epithelial ovarian cancer cells by transactivation of the epidermal growth factor receptor. Endocr Relat Cancer 2010;17(4): 929-40.
11. St Wong, Witte ON. The BCR-ABL story: bench to bedside and back. Annu Rev Immunol 2004;22: 247-306.
12. Smith-Pearson PS, Greuber EK, Yogalingam G, Pendergast AM. Abl kinases are required invadopodia formation and chemokine-induced invasion. J Biol Chem 2010;285(51): 40201-11.
13. Srinivasan D, Plattner R. Activation of Abl tyrosine kinase promotes invasion of aggressive breast cancer cells. Cancer Res 2006;66(11): 5648-55.
14. Srinivasan D, Sims JT, Plattner R. Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival. Oncogene 2008;27(8): 1095-105.
15. Ganguly SS, Fiore LS, Sims JT, Friend JW, Srinivsan D, Thacker MA, et al. c-Abl and Arg are activated in human primary melanomas, promote melanoma cell invasion via distinct pathways, and drive metastatic progression. Oncogene 2012;31(14): 1804-16.
16. Hong J, Peng DF, Chen Z, Vikas Sehdev, Belkhiri A. ABL regulation by AXL promotes cisplatin resistance in esophageal cancer. Cancer Res 2013;73(1): 331-40.
17. Zhang J, Tang LD, Shen LY, Zhou SY, Duan ZN, Xiao L, et al. High level of WAVE1 expression is associated with tumor aggressiveness and unfavorable prognosis of epithelial ovarian cancer. Gynecol Oncol 2012;127(1): 223-30.
18. Miki H, Takenawa T. Regulation of actin dynamics byWASP family protein. J Biochem 2003;134(3): 309-19.
19. Miller MM, Lapetina S, Macgrath SM, Sfakianos MK, Pollard TD, Koleske AJ. Regulation of actin polymerization and adhesion-dependent cell edge protrusion by the Abl-related gene (Arg) tyrosine kinase and N-W-ASp. Biochemistry 2010;49(10): 2227-34.
20. Heng JI, Chariot A, Nguyen L. Molecular layers underlying cytoskeletal remodeling during cortical development. Trends Neurosci 2010;33(1): 38-47.
21. Bradley WD, Koleske AJ. Regulation of cell migration and morphogenesis by Abl-family kinases: emerging mechanisms and physiological contexts. J Cell Sci 2009;122(19): 3441-54.
22. Westphal RS, Soderling SH, Alto NM, Langeberg LK, Scott JD. Scar/WAVE-1, a Wiskott-Aldrich syndrome protein, assembles an actin-associated multi-kinase scaffold. EMBO J 2000;19(17): 4589-600.
23. Au CW, Siu MK, Liao X, Wong ES, Ngan HY, Tam KF, et al. Tyrosine kinase B receptor and BDNF expression ovarian cancers-effect on cell migration, angiogenesis and clinical outcome. Cancer Lett 2009;281(2) [15-1-61].
24. Erhong Meng, Brandon Taylor, Anasuya Ray, Shevde LA, Rocconi RP. Targeted inhibition of telomerase activity combined with chemotherapy demonstrates synergy in eliminating ovarian cancer spheroid-forming cells. Gynecol Oncol 2012;124(3): 598-605.
25. Ayala I, Baldassarre M, Giacchetti G, Giusi Caldieri, Tetè S, Luini A, et al. Multiple regulatory inputs converge on cortactin to control invadopodia biogenesis and extracellular matrix degradation. J Cell Sci 2008;1-21(3): 369-78.
26. Gimona M, Buccione R, Courtneidge SA, Linder S. Assembly and biological role of podosomes and invadopodia. Curr Opin Cell Biol 2008;20(2): 235-41.
27. Astro V, Asperti C, Cangi G, Doglioni C, De CI. Liprin-α 1 regulates breast cancer cell invasion by affecting cell motility, invadopodia and extracellular matrix degradation. Oncogene 2011;30(15): 1841-9.
28. Ann Marie Pendergast. The family kinases: mechanisms of regulation and signaling. Adv Cancer Res 2002;8-5: 51-100.
29. Singer CF, Hudelist G, Lamm W, Ruth Mueller, Czerwenka K, Kubista E. Expression of tyrosine kinases in human malignancies as potential targets for kinase-specific inhibitors. Endocr Relat Cancer 2004;11(4): 861-9.
30. Lin J, Sun T, Ji L, Deng W, Roth J, Minna J, et al. Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product FUS1. Oncogene 2007;26(49): 6989-96.
31. Nagano K, Itagaki C, Izumi T, Nunomura k, Soda Y, Tani K, et al. Rb plays a role in survival of Abl-dependent human tumor cells as a downstream effector of Abl tyrosine kinase. Oncogene 2006;25(4): 493-502.
32. Koos B, Jeibmann A, Lünenbürger H, Mertsch S, Nupponen NN, Roselli A, et al. The tyrosine kinase c-Abl promotes proliferation and is expressed in atypical teratoid and malignant rhabdoid tumors. Cancer 2010;116(21): 5075-81.
33. Coleman RL, Broaddus RR, Bodurka DC,Wolf JK, Burke TW, Kavanagh JJ, et al. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol Oncol 2006;101(1): 126-31.